Alzheimer's Disease Research Center

总结 最近的研究阿尔茨海默病的诊断标准需要生物标志物评估（如 脑β淀粉样斑块、Tau缠结和神经变性的神经成像和/或脑脊液） （A/T/N），使得能够检测活体个体中AD神经病理学的存在（或不存在），以及 允许AD被诊断和分期，而干预可能是可行的。拟议补编 根据NIH赞助的SCAN协议，寻求获得前瞻性PET和MRI数据， 使用A/T/N框架对个人进行分类，特别是针对西奈山ADRC的少数民族参与者 临床队列，以检查A/T/N生物标志物及其 与认知和其他因素的关系。在少数民族群体中获得A/T/N谱特别重要， 重要性，因为阿尔茨海默氏症类型的痴呆症不成比例地影响少数群体 （特别是美国的非洲裔和西班牙裔人口）。尽管患病率较高， 在少数民族中，他们不太可能被诊断出患有阿尔茨海默病，或者更有可能被诊断出患有阿尔茨海默病。 在疾病诊断后比他们可比的非少数民族同行。拟议补编 试图通过提供在阿尔茨海默氏症患者中广泛分布的少数人的数据来帮助填补这一空白 疾病研究社区。由西奈山阿尔茨海默病研究中心维持的队列 非常适合检查成像生物标志物中的种族差异，因为超过40%的队列是 由少数民族参与。补充的目的是：1）建立SCAN采集和数据 在我们的站点传输协议并验证现场扫描器，2）在少数情况下获取SCAN协议 在西奈山的40名参与者的队列足以使用A/T/N框架来表征个体，以及3） 研究记忆受损的少数民族参与者中淀粉样变性的低患病率是否可以 这可以通过tau蛋白病、神经变性或血管负担的更高患病率来解释。这些目标既有 实际和科学意义，并将导致数据使用标准化的扫描协议上， 这些数据可以被广泛分享和分发，以进一步研究阿尔茨海默病。 将通过补充获得的数据与非补充获得的数据进行比较， 少数参与者的特点是与其他资源获得的SCAN兼容的协议，以检查 生物标志物谱的种族差异。

SUMMARY Recent research diagnostic criteria for Alzheimer’s Disease require biomarker evaluation (as with neuroimaging and/or cerebrospinal fluid) of brain β Amyloid plaques, Tau tangles, and Neurodegeneration (A/T/N), enabling detection of the presence (or absence) of AD neuropathology in living individuals, and allowing AD to be diagnosed and staged while intervention maybe be feasible. The proposed supplement seeks to acquire prospective PET and MRI data in accordance with the NIH-sponsored SCAN protocols to classify individuals using the A/T/N framework, specifically for minority participants in the Mount Sinai ADRC Clinical Cohort to enable examination of racial disparities in the prevalence of A/T/N biomarkers and their association with cognition and other factors. Acquisition of A/T/N profiles in minority cohorts are of particular significance because dementia of the Alzheimer’s type disproportionately impacts minority populations (particularly African American and Hispanic populations in the United States). Despite higher prevalence rates among minorities, they are less likely to receive a diagnosis of Alzheimer’s disease or are more likely to be diagnosed later in the disease than their comparable non-minority counterparts. The proposed supplement seeks to help fill this gap by providing data on a minority that can be widely distributed among the Alzheimer’s disease research community. The cohort maintained by the Mount Sinai Alzheimer’s Disease Research Center is well-suited to examine racial disparities in imaging biomarkers given that over 40% of the cohort is comprised of minority participants. The supplement aims will: 1) establish the SCAN acquisition and data transfer protocols at our site and validate the on-site scanner, 2) acquire the SCAN protocol on a minority cohort of 40 participants at Mount Sinai sufficient to characterize individuals using the A/T/N framework, and 3) examine whether low prevalence of amyloidosis among memory-impaired minority participants can be explained by higher prevalence of tauopathy, neurodegeneration, or vascular burden. These aims have both practical and scientific significance and will result in data using the standardized SCAN protocol on an underserved population that can be widely shared and distributed to further Alzheimer’s disease research. Scientific significance will be achieved by comparing the data acquired through the supplement with non- minority participants characterized on SCAN-compatible protocols acquired with other resources to examine racial disparities in biomarker profiles.